A phase II study of docetaxel in patients with metastatic squamous cell carcinoma of the head and neck (original) (raw)

References

• Aapro, M, Zulian, G, Alberto, P, Bruno, R, Oulid-Aissa, D & Le Bail, N (1992). Phase I and pharmacokinetic study of RP56976 in a new ethanol free formulation. Ann Oncol 3: (abstract 208)
  Google Scholar
• Armand, JP & Couteau, C (1995). Chemotherapy in head and neck treatment. Eur J Cancer 5: 819–822.
  Article Google Scholar
• Bissery, MC, Guenard, D & Gueritte-Voegelein, F (1991). Experimental antitumor activity of taxotere, a taxol analogue. Cancer Res 51: 4845–4852.
  CAS Google Scholar
• Bissett, D, Setanoians, A, Cassidy, J, Graham, MA, Chadwick, GA, Wilson, P, Auzannet, V, Le Bail, N, Kaye, SB & Kerr, DJ (1993). Phase I and pharmacokinetic study of taxotere administered as infusion. Cancer Res 53: 523–527.
  CAS PubMed Google Scholar
• Braakhuis, BJM, Kagel, A & Welters, MJP (1994). The growth inhibiting effect of docetaxel (taxotere) in head and neck squamous cell carcinoma xenografts. Cancer Lett 81: 151–154.
  Article CAS Google Scholar
• Bruno, R, Hille, D, Riva, A, Vivier, N, Bokkel Huinnink, W, van Oosterom, A, Kaye, S, Verweij, J, Fossella, F, Valero, V, Rigas, J, Seidman, A, Chevallier, B, Fumoleau, P, Burris, H, Ravdin, P & Sheiner, L (1998). Population pharmacokinetics/ pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 1: 187–196.
  Article Google Scholar
• Burris, H, Irvin, R, Kuhn, J, Kalter, S, Smith, L, Shaffer, D, Fields, S, Weiss, G, Eckart, J, Rodriguez, G, Rinaldi, D, Wall, J, Cook, G, Smith, S, Vreeland, F, Bayssas, M, Le Bail, N & Von Hoff, D (1993). Phase I clinical trial of taxotere administered as either a 2 hour or 6 hour intravenous infusion. J Clin Oncol 11: 950–958.
  Article CAS Google Scholar
• Catimel, G, Verweij, J, Mattijssen, V, Hanauska, A, Piccart, M, Vanders, J, Franklin, H, Le Bail, N & Kaye, SB (1994a). Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. Ann Oncol 5: 533–537.
  Article CAS Google Scholar
• Catimel, G, Vermorken, JB, Clavel, M, DeMulder, P, Judsen, I, Sessa, C, Piccart, M, Bruntsch, U, Verweij, J, Wanders, J, Franklin, H & Kaye, SB (1994b). A phase II study of gemcitabine in patients with advanced squamous cell carcinoma of the head and neck. Ann Oncol 5: 543–547.
  Article CAS Google Scholar
• Dreyfuss, AI, Clark, JR, Norris, CM, Rossi, RM, Lucarini, JW, Busse, PM, Poulin, MD, Thornhil, L, Costello, R & Posner, MR (1996). Docetaxel an active new drug for squamous cell carcinoma of the head and neck. J Clin Oncol 14: 1672–1678.
  Article CAS Google Scholar
• Extra, JM, Rousseau, F, Bruno, R, Clavel, M, le Bail, N & Marty, M (1993). Phase I and pharmacokinetic study of taxotere given as a short intravenous infusion. Cancer Res 53: 1037–1042.
  CAS PubMed Google Scholar
• Forastiere, AA, Neuberg, D, Taylor, IVSG, De Conti, R & Adams, G (1993). Phase II evaluation of Taxol in advanced head and neck cancer: an eastern cooperative oncology group trial. J Natl Cancer Inst Monogr 15: 181–183.
  Google Scholar
• Fujii, H, Sasaki, Y, Ebihara, S, Kida, Y, Ichikawa, G & Kaniyawa, S (1955). An early phase II study of docetaxel (taxotere) in patients with head and neck cancer. Proc Am Soc Clin Oncol 14: 298 (abstr 859)
  Google Scholar
• Gandia, D, Wibault, P, Guillot, T, Bensmaine, A, Armand, JP, Marandas, P, Luboinski, B & Cvitkovic, E (1993). Simultaneous chemoradiotherapy as salvage treatment in locoregional recurrences of squamous head and neck cancer. Head Neck 15: 8–15.
  Article CAS Google Scholar
• Gebbia, V, Testa, A, Valenza, R, Zerillo, G, Restivo, S, Ingria, F, Cannata, G & Gebbia, N (1993). A pilot study of vinorelbine on a weekly schedule in recurrent and/or metastatic squamous cell carcinoma of the head and neck. Eur J Cancer 29A 9: 1358–1359.
  Article Google Scholar
• Gebbia, V, Testa, A, Cannata, G & Gebbia, N (1996). Single agent paclitaxel in advanced squamous cell head and neck carcinoma. Eur J Cancer 5: 901–902.
  Article Google Scholar
• Landis, SH, Murray, T, Bolden, S & Wingo, PH (1998). Cancer statistics, 1998. Cancer J Clin 48: 6–29.
  Article CAS Google Scholar
• Pazdur, R, Newman, RA & Newman, BM (1992). Phase I trial of Taxotere: five days schedule. J Natl Cancer Inst 84: 1781–1788.
  Article CAS Google Scholar
• Ravdin, P, Valero, V, Nabholtz, JM, Hortobagyi, G, Oulid-Aissa, D, Riva, A, Houver, C & Bellet, R (1996). Efficacy of 5 day corticosteroid premedication in ameliorating taxotere induced fluid retention. Proc Am Soc Clin Oncol 14: 115 (abstract 124)
  Google Scholar
• Recondo, G, Armand, JP, Tellez-Bernal, E, Domenge, C, Belehradek, M, De Vathaire, F, Wibault, P, Richard, JM & Cvitkovic, E (1991). Recurrent and/or metastatic head and neck squamous cell carcinoma: a clinical, univariate, and multivariate analysis of response and survival with cisplatin-based chemotherapy. Laryngoscope 101: 494–501.
  Article CAS Google Scholar
• Riou, JF, Naudin, A & Lavelle, F (1992). Effects of taxotere on murine and human tumor cell lines. Biochem Biophys Res Commun 187: 164–170.
  Article CAS Google Scholar
• Robert, F, Wheeler, RH, Molthrop, DC, Greene, P & Chen, S (1994). Phase II study of topotecan in advanced head and neck cancer, identification of an active new agent. Proc Am Soc Clin Oncol 13: 281 (abstract 905)
  Google Scholar
• Schornagel, JH, Verweij, J, De Mulder, PH, Cognetti, F, Vermorken, JP, Cappeleare, Armand, JP, Wildiers, J, Clavel, M & Kirkpatrick, A et al (1992). Phase II trial of 10 ethyl 10 deaza aminopterin, a novel antifolate, in patients with advanced and/or recurrent squamous cell carcinoma of the head and neck. Ann Oncol 3: 223–226.
  Article CAS Google Scholar
• Smith, RE, Thornton, DE & Allen, J (1995). A phase II trial of paclitaxel in squamous cell carcinoma of the head and neck with correlative laboratory studies. Semin Oncol 22: 41–46.
  CAS PubMed Google Scholar
• Tanigawara, Y, Sasaki, Y, Otsu, T, Fujii, H, Kashiwura, M, Sasaki, T, Okuamura, K & Taguchi, T (1996). Population pharmacokinetics of docetaxel in Japanese patients. Proc Am Soc Clin Oncol 14: 479 (abstract 1518)
  Google Scholar
• Tomiak, E, Piccart, MJ, Kerger, J, Lips, S, Awada, A, De Valeriola, D, Ravoet, C, Lossignol, D, Sculier, JP, Auzannet, V, Le Bail, N, Bayssas, M & Kastersky, J (1994). Phase I study of docetaxel administered as 1 hour intravenous infusion on a weekly basis. J Clin Oncol 12: 1458–1467.
  Article CAS Google Scholar
• Verweij, J (1995). Docetaxel, an interesting new drug for the treatment of head and neck cancer and soft tissue sarcomas. Anti Cancer Drugs 6: 19–24.
  Article CAS Google Scholar
• Vokes, EE, Awan, AM & Weichselbaum, RR (1991). Radiotherapy with concomitant chemotherapy for head and neck cancer. Hematol/Oncol Clin N Am 5: 753–767.
  Article CAS Google Scholar
• Vokes, EE, Weichselbaum, PP, Lippman, SM & Hong, WK (1993). Head and neck cancer. N Engl J Med 328: 184–194.
  Article CAS Google Scholar

Download references